Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors

A. D. Hess, R. Catchatourian, A. R. Zander, R. B. Epstein

Research output: Contribution to journalArticle

Abstract

Canine transmissible venereal tumors were studied for response to intralesional Bacillus Calmette-Guerin (BCG) therapy. Six pairs of littermates, identical for the major histocompatibility complex, were evaluated. One member of each pair received intralesional BCG to one of two growing tumors. Lesions of control animals received 0.9% NaCl solution. Both injected and noninjected lesions of BCG-treated animals underwent regression within 63 days, as compared to an extended period of tumor growth (beyond 100 days) for controls (p <0.05). Serial in vitro assays during therapy included: (a) mixed lymphocyte-tumor culture, (b) phytohemagglutinin stimulation, and (c) assessment of lymphocyte surface markers. Lymphocytes from BCG-treated dogs were significantly more responsive to tumor cells in mixed lymphocyte-tumor culture assay than were those from controls (p <0.05). Maximal responses occurred during tumor regression. T- and B-lymphocyte levels as assayed by rosette formation and surface marker immunoglobulins were not influenced by BCG therapy. It was concluded that intralesional BCG therapy of canine venereal tumors was highly effective in causing regression of injected and noninjected lesions. This tumor model system may be useful for the evaluation of the effectiveness of new immunotherapeutic approaches on established neoplasms in large, randomly bred animals.

Original languageEnglish (US)
Pages (from-to)3990-3994
Number of pages5
JournalCancer Research
Volume37
Issue number11
StatePublished - 1977
Externally publishedYes

Fingerprint

Mycobacterium bovis
Immunotherapy
Canidae
Neoplasms
Lymphocytes
Veterinary Venereal Tumors
Rosette Formation
B-Cell Antigen Receptors
Phytohemagglutinins
Therapeutics
Major Histocompatibility Complex
B-Lymphocytes
Dogs
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hess, A. D., Catchatourian, R., Zander, A. R., & Epstein, R. B. (1977). Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors. Cancer Research, 37(11), 3990-3994.

Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors. / Hess, A. D.; Catchatourian, R.; Zander, A. R.; Epstein, R. B.

In: Cancer Research, Vol. 37, No. 11, 1977, p. 3990-3994.

Research output: Contribution to journalArticle

Hess, AD, Catchatourian, R, Zander, AR & Epstein, RB 1977, 'Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors', Cancer Research, vol. 37, no. 11, pp. 3990-3994.
Hess AD, Catchatourian R, Zander AR, Epstein RB. Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors. Cancer Research. 1977;37(11):3990-3994.
Hess, A. D. ; Catchatourian, R. ; Zander, A. R. ; Epstein, R. B. / Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors. In: Cancer Research. 1977 ; Vol. 37, No. 11. pp. 3990-3994.
@article{3dd7b045b70e4ab49b6c50c4aa383525,
title = "Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors",
abstract = "Canine transmissible venereal tumors were studied for response to intralesional Bacillus Calmette-Guerin (BCG) therapy. Six pairs of littermates, identical for the major histocompatibility complex, were evaluated. One member of each pair received intralesional BCG to one of two growing tumors. Lesions of control animals received 0.9{\%} NaCl solution. Both injected and noninjected lesions of BCG-treated animals underwent regression within 63 days, as compared to an extended period of tumor growth (beyond 100 days) for controls (p <0.05). Serial in vitro assays during therapy included: (a) mixed lymphocyte-tumor culture, (b) phytohemagglutinin stimulation, and (c) assessment of lymphocyte surface markers. Lymphocytes from BCG-treated dogs were significantly more responsive to tumor cells in mixed lymphocyte-tumor culture assay than were those from controls (p <0.05). Maximal responses occurred during tumor regression. T- and B-lymphocyte levels as assayed by rosette formation and surface marker immunoglobulins were not influenced by BCG therapy. It was concluded that intralesional BCG therapy of canine venereal tumors was highly effective in causing regression of injected and noninjected lesions. This tumor model system may be useful for the evaluation of the effectiveness of new immunotherapeutic approaches on established neoplasms in large, randomly bred animals.",
author = "Hess, {A. D.} and R. Catchatourian and Zander, {A. R.} and Epstein, {R. B.}",
year = "1977",
language = "English (US)",
volume = "37",
pages = "3990--3994",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Intralesional Bacillus Calmette-Guerin immunotherapy of canine venereal tumors

AU - Hess, A. D.

AU - Catchatourian, R.

AU - Zander, A. R.

AU - Epstein, R. B.

PY - 1977

Y1 - 1977

N2 - Canine transmissible venereal tumors were studied for response to intralesional Bacillus Calmette-Guerin (BCG) therapy. Six pairs of littermates, identical for the major histocompatibility complex, were evaluated. One member of each pair received intralesional BCG to one of two growing tumors. Lesions of control animals received 0.9% NaCl solution. Both injected and noninjected lesions of BCG-treated animals underwent regression within 63 days, as compared to an extended period of tumor growth (beyond 100 days) for controls (p <0.05). Serial in vitro assays during therapy included: (a) mixed lymphocyte-tumor culture, (b) phytohemagglutinin stimulation, and (c) assessment of lymphocyte surface markers. Lymphocytes from BCG-treated dogs were significantly more responsive to tumor cells in mixed lymphocyte-tumor culture assay than were those from controls (p <0.05). Maximal responses occurred during tumor regression. T- and B-lymphocyte levels as assayed by rosette formation and surface marker immunoglobulins were not influenced by BCG therapy. It was concluded that intralesional BCG therapy of canine venereal tumors was highly effective in causing regression of injected and noninjected lesions. This tumor model system may be useful for the evaluation of the effectiveness of new immunotherapeutic approaches on established neoplasms in large, randomly bred animals.

AB - Canine transmissible venereal tumors were studied for response to intralesional Bacillus Calmette-Guerin (BCG) therapy. Six pairs of littermates, identical for the major histocompatibility complex, were evaluated. One member of each pair received intralesional BCG to one of two growing tumors. Lesions of control animals received 0.9% NaCl solution. Both injected and noninjected lesions of BCG-treated animals underwent regression within 63 days, as compared to an extended period of tumor growth (beyond 100 days) for controls (p <0.05). Serial in vitro assays during therapy included: (a) mixed lymphocyte-tumor culture, (b) phytohemagglutinin stimulation, and (c) assessment of lymphocyte surface markers. Lymphocytes from BCG-treated dogs were significantly more responsive to tumor cells in mixed lymphocyte-tumor culture assay than were those from controls (p <0.05). Maximal responses occurred during tumor regression. T- and B-lymphocyte levels as assayed by rosette formation and surface marker immunoglobulins were not influenced by BCG therapy. It was concluded that intralesional BCG therapy of canine venereal tumors was highly effective in causing regression of injected and noninjected lesions. This tumor model system may be useful for the evaluation of the effectiveness of new immunotherapeutic approaches on established neoplasms in large, randomly bred animals.

UR - http://www.scopus.com/inward/record.url?scp=0017753947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017753947&partnerID=8YFLogxK

M3 - Article

C2 - 143344

AN - SCOPUS:0017753947

VL - 37

SP - 3990

EP - 3994

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -